Peptide / Metabolic

Cagrilintide

Long-acting amylin analogue (once-weekly). Slows gastric emptying, reduces appetite via hypothalamic pathways, and reduces caloric intake. Phase 3 trials in combination with semaglutide (CagriSema). Amylin pathway is complementary to GLP-1 — combination shows superior weight loss vs either alone.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose0.16–2.4 mg SubQ once weekly (titrate from 0.16 mg)

Half-life168 hours

Risk flagmoderate

Regulatory noteResearch-only flag

Side effects and watch-outs

Nausea (most common, especially on titration)
Vomiting
Decreased appetite
Injection site reaction
Headache
Dizziness
⚠️ Hypoglycaemia risk when combined with insulin or other glucose-lowering agents
Constipation
Fatigue on initiation